The TAILORx results provide definitive answers
"Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision" said lead author Joseph A. Sparano, MD. "The 21-gene assay ... [can] identify the 70% of women with no chemotherapy benefit, and the others where chemotherapy may be life-saving." Know with confidence who will benefit from chemotherapy and who will not.1-4
The largest randomized adjuvant breast cancer trial ever conducted, the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute.
Read the article on NEJM.org
As presented at ASCO 2019, a new analysis of TAILORx confirms the original, definitive conclusions reported previously with additional detail on clinical risk, focusing on patients with early-stage breast cancer who are age 50 years or younger.
See the new analysis on NEJM from ASCO 2019
As presented at ESMO 2019, a new, secondary analysis of TAILORx, highlighted clinical outcomes in patients with a Recurrence Score result of 26‐100. This new analysis reinforces the definitive results of TAILORx, that only the Oncotype DX Breast Recurrence Score test identifies patients who will and will not benefit from chemotherapy.
See the new analysis on JAMA Oncology